Filing Flows › Eton Pharmaceuticals (ETON) › Q2 2026 › vs Q1 2026
Eton Pharmaceuticals (ETON) Q2 2026 vs Q1 2026 (quarter over quarter)
Eton Pharmaceuticals's revenue rose $13.3M (+55%) from $24.3M in Q1 2026 to $37.6M in Q2 2026. Gross margin 67.6% against 60.7% (+6.9 pts).
Eton Pharmaceuticals, Q2 2026: revenue $37.6M (+99% year over year), operating margin 34.0%, net earnings $11.6M, operating cash flow $7.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 67.6% | 60.7% | +6.9 pts |
| Operating margin | 34.0% | 9.9% | +24.1 pts |
| Net margin | 30.8% | 6.4% | +24.4 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $37.6M | $24.3M | $13.3M | +55% |
| Gross profit | $25.4M | $14.7M | $10.7M | +72% |
| Cost of revenue | $12.2M | $9.5M | $2.6M | +28% |
| Operating profit | $12.8M | $2.4M | $10.4M | +430% |
| Operating expenses | $12.6M | $12.3M | $298K | +2% |
| Pre-tax earnings | $11.7M | $1.6M | $10.1M | +644% |
| Other expense, net | $1.1M | $840K | $236K | +28% |
| Research & development | $993K | $1.9M | −$882K | -47% |
| General & admin | $11.6M | $10.4M | $1.2M | +11% |
| Net earnings | $11.6M | $1.6M | $10.0M | +645% |
| Income tax | $140K | $20K | $120K | +600% |
| Depreciation & amortization | $1.4M | $1.1M | $255K | +23% |
| Share-based compensation | $1.5M | $1.5M | −$50K | -3% |
| Working capital & other | $7.2M | −$3.2M | $10.4M | — |
| Operating cash flow | $7.3M | $7.4M | −$150K | -2% |
Questions
How much did Eton Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Eton Pharmaceuticals's revenue rose $13.3M (+55%) from $24.3M in Q1 2026 to $37.6M in Q2 2026. Gross margin 67.6% against 60.7% (+6.9 pts).